open access

Vol 27, No 4 (2020)
Study protocol — COVID-19
Published online: 2020-06-29
Get Citation

Ion channel inhibition against COVID-19: A novel target for clinical investigation

Eliano P. Navarese, Rita L. Musci, Lara Frediani, Paul A. Gurbel, Jacek Kubica
DOI: 10.5603/CJ.a2020.0090
·
Pubmed: 32643141
·
Cardiol J 2020;27(4):421-424.

open access

Vol 27, No 4 (2020)
Study protocol — COVID-19
Published online: 2020-06-29

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Ion channel inhibition against COVID-19: A novel target for clinical investigation

Journal

Cardiology Journal

Issue

Vol 27, No 4 (2020)

Pages

421-424

Published online

2020-06-29

DOI

10.5603/CJ.a2020.0090

Pubmed

32643141

Bibliographic record

Cardiol J 2020;27(4):421-424.

Authors

Eliano P. Navarese
Rita L. Musci
Lara Frediani
Paul A. Gurbel
Jacek Kubica

References (15)
  1. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020; 39(5): 405–407.
  2. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2): 271–280.e8.
  3. Inoue Y, Tanaka N, Tanaka Y, et al. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J Virol. 2007; 81(16): 8722–8729.
  4. Lai AL, Millet JK, Daniel S, et al. The SARS-CoV fusion peptide forms an extended bipartite fusion platform that perturbs membrane order in a calcium-dependent manner. J Mol Biol. 2017; 429(24): 3875–3892.
  5. Straus MR, Tang T, Lai AL, et al. Ca ions promote fusion of middle east respiratory syndrome coronavirus with host cells and increase infectivity. J Virol. 2020; 94(13).
  6. Qian Z, Dominguez SR, Holmes KV. Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PLoS One. 2013; 8(10): e76469.
  7. Tang T, Bidon M, Jaimes JA, et al. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antiviral Res. 2020; 178: 104792.
  8. Basso LGM, Vicente EF, Crusca E, et al. SARS-CoV fusion peptides induce membrane surface ordering and curvature. Sci Rep. 2016; 6: 37131.
  9. de Haan CAM, Rottier PJM. Molecular interactions in the assembly of coronaviruses. Adv Virus Res. 2005; 64: 165–230.
  10. Raffaello A, Mammucari C, Gherardi G, et al. Calcium at the center of cell signaling: interplay between endoplasmic reticulum, mitochondria, and lysosomes. Trends Biochem Sci. 2016; 41(12): 1035–1049.
  11. Huotari J, Helenius A. Endosome maturation. EMBO J. 2011; 30(17): 3481–3500.
  12. Pryor PR, Mullock BM, Bright NA, et al. The role of intraorganellar Ca(2+) in late endosome-lysosome heterotypic fusion and in the reformation of lysosomes from hybrid organelles. J Cell Biol. 2000; 149(5): 1053–1062.
  13. Stadler K, Ha HR, Ciminale V, et al. Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. Am J Respir Cell Mol Biol. 2008; 39(2): 142–149.
  14. Gehring G, Rohrmann K, Atenchong N, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014; 69(8): 2123–2131.
  15. Salata C, Baritussio A, Munegato D, et al. Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process. Pathog Dis. 2015; 73(5).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl